View this email in your browser
Share Share
Tweet Tweet
Forward Forward


Bringing you our latest news, features and guidance.
February 2022
COVID-19NewsInto practice | Get involved | Blogs | Other resources |  Announcements


Updates to managing COVID-19 guideline

We have added a new recommendation to our rapid guideline on managing COVID-19 on neutralising monoclonal antibodies for people with COVID-19 who are not in hospital.

We are continuously updating our COVID-19 guidelines to incorporate the latest evidence and keep abreast of new developments in diagnosing and treating COVID-19. We’ll highlight recent updates in this monthly email communication, or you can keep up to date on the latest live changes through our website.


Man speaking to consultant

New diagnostic devices for men with suspected prostate cancer

Our new draft guideline recommends 4 new diagnostic devices for men with suspected prostate cancer that reduce the chances of biopsy related sepsis. These are freehand needle positioning devices used to perform local anaesthetic transperineal (LATP) prostate biopsy. Evidence presented to the committee suggested that the detection rates of cancer did not differ significantly between a transrectal ultrasound guided (TRUS) biopsy, which is one of the current NICE recommended interventions, and an LATP biopsy using a freehand needle positioning device. However, the LATP procedure was shown to greatly reduce the risk of biopsy-related sepsis and potentially hospital admissions, compared with a TRUS biopsy. Consultation is open until Tuesday 8 March 2022.

A picture of the actual drug Wegovy

New drug for people living with obesity

Thousands of people living with obesity are set to benefit from a new drug that could help reduce their weight by more than 10 per cent. Our new draft guidance recommends semaglutide is offered as an option for weight management, alongside a reduced-calorie diet and increased physical activity. Adults must have at least 1 weight-related condition and a body mass index (BMI) of at least 35 kg/m2, or exceptionally, a BMI of 30.0 kg/m2 to 34.9 kg/m2 to be considered for treatment. Evidence submitted shows that people lose more weight with semaglutide alongside supervised weight loss coaching than with support alone. Consultation is open until Tuesday 1 March 2022.

First gene therapy for rare genetic neurodegenerative disorder in children

We've published draft guidance recommending gene therapy atidarsagene autotemcel as a one-off treatment for some children with the rare, life-limiting neurodegenerative condition metachromatic leukodystrophy (MLD). Clinical evidence suggests that atidarsagene autotemcel improves motor and cognitive function in the short term and could correct the enzyme deficiency caused by the disease. It is thought there are around 5 children born each year in England with MLD. Costing around £2.8 million at its list price, this one-off treatment is the most expensive drug NICE has ever evaluated. 

Catch up on our latest news
NICE Talk logo

The Evidence Standards Framework for digital health technologies

In this episode of our NICE Talks podcast, Mark Salmon, programme director at NICE and Andrew Davies, digital health lead at the Association of British HealthTech Industries discuss our Evidence Standards Framework for digital health technologies. The framework helps developers and adopters of digital health technologies ensure new technologies are clinically effective and offer economic value.

Into practice

Improving outcomes for cardiovascular disease (CVD)

The Accelerated Access Collaborative’s (AAC) lipid management rapid uptake product working group aims to remove barriers to the uptake of 3 NICE recommended lipid-lowering therapies:

  • high intensity statins
  • ezetimibe
  • PCSK9 inhibitors.
To support best treatment for patients with hypercholesterolaemia, the working group has developed 2 NICE-endorsed clinical pathways. These incorporate a number of our guidelines and technology appraisals:

The AAC has also produced a slide deck updating on their progress. This includes a list of resources (Slide 4) to help improve patient lipid management outcomes.

BNF app introducing new login and favourites functionality

The BNF app is introducing new favourites functionality. It will allow registered users to login and bookmark drug monographs, treatment summaries and other records referred to frequently. This will allow users to easily find and quickly access this content across multiple devices.

Registration is required to help support the new feature. It’s quick and easy to do and once logged in, you will stay signed in on your device. Registration will be optional for 30 days from Monday 28 February 2022. During this time, users will be able to skip the registration process and access the app as usual. After 30 days, all users will be required to register.

Get involved

Comment on a consultation

Our current consultations include:

Consultation is a key part of our guidance development process. It enables those with an interest in our guidance to comment at specific stages and feedback into the decision-making process.
See all our open consultations

Join a committee

We have 7 vacancies for health, public health and social care practitioners, other professionals, and lay people to join our committees. Topics include menopause, harmful gambling, prostate cancer and adrenal insufficiency. We’re also looking for a commissioner of surgical services to join our hip fracture: management update committee. Join us and have an active role in producing a guideline or quality standard.

See all our committee vacancies

Observe a meeting

We’re currently holding all our public meetings virtually. You'll need to register in advance to join. 

Upcoming public meeting:

  • Tuesday 8 March 2022 – indicator advisory committee
    Registration closes Tuesday 1 March 2022.
    Agenda and register
Our advisory committee meetings, technology appraisal appeal hearings and public board meetings are open to the public. Holding them in public supports our commitment to having processes in place that are rigorous, open, and transparent.
See all our public meetings


Toni Gasse

Putting user-needs at the heart of a multi-agency advisory service for AI

Toni Gasse, project manager for the multi-agency advisory service secretariat explains how user needs are being placed front and centre to develop a multi-agency advisory service for artificial intelligence (AI) and data-driven technologies.

Richard Chivers

How NICE is supporting digital health technology developers

Richard Chivers, operations manager, NICE Scientific Advice, outlines how we’ve been supporting digital health technology developers who’ve been awarded funding from the Digital Health Technology Catalyst, managed by UK Research and Innovation. Richard explains how our support has focussed on helping successful bid winners to determine the evidence required for their products to be adopted by the NHS.

Shane Collins

NIHR funding call to address NICE research recommendations

Shane Collins, technical analyst within the NICE Science Policy and Research Programme tells us why the National Institute for Health Research (NIHR) has launched a rolling funding call for studies addressing our research recommendations and how to get involved.

Read more of our latest blog posts

Other resources

New toolkit to help social care providers prepare for CQC inspections

Developed by Skills for Care in partnership with NICE and the Social Care Institute for Excellence, the Go Online inspection toolkit is designed to support providers in meeting the Care Quality Commission’s (CQC) quality standards. It also helps users to identify areas for improvement in-line with the CQC’s assessment framework.


Consultation on Evidence-based Interventions Programme

The Academy of Medical Royal Colleges (AMRC) is consulting on the latest set of guidance (List 3) for their Evidence-based Interventions Programme.
The programme provides guidance on when it is and is not appropriate to carry out specific interventions. It aims to improve quality of care and optimise the use of NHS resources. The new guidance covers 17 interventions across a range of specialisms.

The consultation is open until Thursday 31 March 2022.

Share your views on the AMRC evidence-based interventions list

Price increase for technology appraisals and highly specialised technologies

We are increasing our charges for technology and highly specialised technology appraisals. The updated fees will apply to evaluations with a formal start date (invitation to participate) on or after 1 April 2022. Small companies meeting the criteria will continue to receive a 75% discount.

View updated charges

unsubscribe from this list